Drugs / 6MW3511
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05524194 | Oct 2022 → Jun 2024 | cancer | Mabwell (Shanghai) Bioscience Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 6MW3511 | “Subjects will receive 6MW3511 by intravenous administration.” NCT05524194 ↗ |
| Route | Intravenous | “Subjects will receive 6MW3511 by intravenous administration.” NCT05524194 ↗ |